GlassScriptPhysician profile
Clay T Buchanan
NPI 1578900486
$3,335.83
in general payments reported to CMS, 2019-2025
30 companies · $522 in 2025
The $522 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $733 · 2020: $191 · 2021: $691 · 2022: $279 · 2023: $701 · 2024: $220 · 2025: $522.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,443.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,443.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $571.77 | 2019-2024 | Senza |
| Abbvie INC. | $466.03 | 2021-2025 | Ubrelvy, Vraylar, Qulipta |
| Bayer Healthcare Pharmaceuticals INC. | $448.86 | 2021-2025 | |
| Allergan, INC. | $359.99 | 2019-2020 | |
| Medtronic, INC. | $260.48 | 2021-2024 | Linq II, Vanta Adaptivestim |
| Novo Nordisk INC | $165.13 | 2019-2025 | Rybelsus, Ozempic |
| Lilly USA, LLC | $147.13 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Sunovion Pharmaceuticals INC. | $125.32 | 2019 | |
| Globus Medical, INC. | $114.83 | 2025 | Senza |
| Abbott Laboratories | $83.65 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $66.15 | 2019-2025 | Trintellix |
| Biohaven Pharmaceutical Holding Company LTD. | $56.48 | 2022 | |
| Exact Sciences Corporation | $54.75 | 2023-2025 | Cologuard Collection Kit |
| Glaxosmithkline, LLC. | $42.75 | 2023-2025 | Trelegy Ellipta, Arexvy |
| Amgen INC. | $42.61 | 2022-2023 | Repatha, Otezla |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $41.53 | 2021-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $39.41 | 2025 | Caplyta |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.43 | 2023-2025 | Xifaxan |
| Astrazeneca Pharmaceuticals LP | $27.01 | 2021-2025 | Farxiga |
| Optinose US, INC. | $22.40 | 2023 | |
| Neurocrine Biosciences, INC. | $22.15 | 2023 | Ingrezza, Ongentys |
| Inspire Medical Systems, INC. | $20.81 | 2025 | Inspire |
| Pfizer INC. | $20.24 | 2023 | |
| Astellas Pharma US INC | $17.88 | 2023 | Myrbetriq |
| Janssen Pharmaceuticals, INC | $14.61 | 2020 | |
| Sumitomo Pharma America, INC. | $14.53 | 2025 | Gemtesa |
| Biohaven Pharmaceuticals, INC. | $13.53 | 2021 | |
| Antares Pharma, INC. | $13.38 | 2024 | Xyosted |
| Halozyme INC | $13.09 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $11.90 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Clay Buchanan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.